Mimedx Group (MDXG) reported $419M in revenue for fiscal 2025, +20.0% year on year. That ranks #2328 by revenue among 2853 SEC filers and #226 in Healthcare. Net income was $48.6M, a net margin of 11.6%. Revenue has grown 7.3% a year on average since 2016 ($222M then). The fiscal 2025 balance sheet shows $343M in total assets, $166M in cash and $16.5M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $419M | +20.0% | FY20252025-12-31 |
| Gross profitGrossProfit | $346M | +19.7% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $63.9M | +8.5% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $48.6M | +14.5% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $74.0M | +11.8% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $2.0M | +31.2% | FY20232023-12-31 |
| Total assetsAssets | $343M | +29.8% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $257M | +32.9% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $166M | +59.1% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $16.5M | −7.6% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $59.0M | −$10.9M | Open → |
| Q2 20262026-06-30 | $64.4M | −$14.8M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Mimedx Group, Inc.
- Ticker
- MDXG
- Exchange
- Nasdaq
- SIC classification
- Surgical & Medical Instruments & Apparatus (3841)
- Fiscal year end
- 12-31
- CIK
- 0001376339
Filings
- 10-QJul 29, 2026Open filing →
- 10-QApr 29, 2026Open filing →
- 10-KFeb 25, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Tarsus PharmaceuticalsTARS | $451M | −$66.0M |
| ArtivionAORT | $441M | $9.8M |
| Genedx HoldingsWGS | $428M | −$21.0M |
| Mimedx GroupMDXG | $419M | $48.6M |
| InnovivaINVA | $411M | $271M |
| ArdelyxARDX | $407M | −$62.0M |
| Immunocore HoldingsIMCR | $400M | −$35.5M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Mimedx Group — Key figures |url=https://companiesranked.com/en/company/mimedx-group |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Mimedx Group — Key figures. CompaniesRanked. https://companiesranked.com/en/company/mimedx-groupBibTeX
@misc{companiesranked-en-company-mimedx-group-2026,
author = {{CompaniesRanked}},
title = {{Mimedx Group — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/mimedx-group}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001376339-26-000011 · February 25, 2026
{{cite web |title=Mimedx Group — Key figures — 10-K (0001376339-26-000011) |url=https://www.sec.gov/Archives/edgar/data/1376339/000137633926000011/mdxg-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-25}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.